Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical University, No. 119, Southwest 4th Ring Road, Fengtai District, Beijing, People's Republic of China, 100070.
Trials. 2023 Feb 25;24(1):144. doi: 10.1186/s13063-023-07178-3.
Perioperative pain management is one of the most challenging issues for patients with spinal neoplasms. Inadequate postoperative analgesia usually leads to severe postsurgical pain, which could cause patients to suffer from many other related complications. Meanwhile, there is no appropriate analgesic strategy for patients with spinal neoplasms.
METHODS/DESIGN: This is a protocol for a randomized double-blind controlled trial to evaluate the effect of esketamine combined with pregabalin on postsurgical pain in spinal surgery. Patients aged 18 to 65 years scheduled for spinal neoplasm resection will be randomly allocated into the combined and control groups in a 1:1 ratio. In the combined group, esketamine will be given during the during the surgery procedure until 48-h postoperative period, and pregabalin will be taken from 2 h before the surgery to 2 weeks postoperatively. The control group will receive normal saline and placebo capsules at the same time points. Both groups received a background analgesic regimen by using patient-controlled intravenous analgesia (containing 100 μg sufentanil and 16 mg ondansetron) until 2 days after surgery. To ensure the accuracy and reliability of this trial, all the researchers and patients will be blinded until the completion of this study. The primary outcome will be the proportion of patients with acute moderate-to-severe postsurgical pain (visual analog scale, VAS ≥ 40, range: 0-100, with 0, no pain; 100, the worst pain) during the 48-h postoperative period. The secondary outcomes will include the maximal VAS scores (when the patients felt the most intense pain over the last 24 h before being interviewed) at 0-2 h, 2-24 h, 24-48 h, and 48-72 h after leaving the operating room and 24 h before discharge; the incidence of acute moderate-to-severe postsurgical pain at each other time point; chronic postsurgical pain assessment; neuropathic pain assessment; and the incidence of drug-related adverse events and other postoperative complications, such as postoperative delirium and postoperative nausea and vomiting (PONV).
The aim of this study was to evaluate the effect of esketamine combined with pregabalin on acute postsurgical pain in patients undergoing resection of spinal neoplasms. The safety of this perioperative pain management strategy will also be examined.
ClinicalTrials.gov NCT05096468. Registered on October 27, 2021.
围手术期疼痛管理是脊柱肿瘤患者面临的最具挑战性的问题之一。术后镇痛不足通常会导致严重的术后疼痛,这可能会使患者遭受许多其他相关并发症的困扰。同时,脊柱肿瘤患者也没有合适的镇痛策略。
方法/设计:这是一项评估鞘内注射氯胺酮联合普瑞巴林用于脊柱手术术后疼痛的随机双盲对照试验的方案。将年龄在 18 至 65 岁之间、拟行脊柱肿瘤切除术的患者按 1:1 的比例随机分配到联合组和对照组。在联合组中,在手术过程中给予氯胺酮,直至术后 48 小时,普瑞巴林在术前 2 小时至术后 2 周服用。对照组将同时给予生理盐水和安慰剂胶囊。两组均采用患者自控静脉镇痛(含 100 μg舒芬太尼和 16 mg昂丹司琼)进行背景镇痛,直至术后 2 天。为确保试验的准确性和可靠性,所有研究人员和患者在完成本研究之前均保持盲法。主要结局是术后 48 小时内急性中重度术后疼痛(视觉模拟评分,VAS≥40,范围:0-100,0 无疼痛;100 最严重疼痛)的患者比例。次要结局包括术后 0-2 小时、2-24 小时、24-48 小时和离开手术室后 48-72 小时的最大 VAS 评分(在接受采访前最后 24 小时感到最剧烈疼痛时),以及离开手术室后每个时间点的急性中重度术后疼痛发生率;慢性术后疼痛评估;神经病理性疼痛评估;以及药物相关不良事件和其他术后并发症(如术后谵妄和术后恶心呕吐)的发生率。
本研究旨在评估鞘内注射氯胺酮联合普瑞巴林用于脊柱肿瘤切除术患者急性术后疼痛的效果。还将检查这种围手术期疼痛管理策略的安全性。
ClinicalTrials.gov NCT05096468。于 2021 年 10 月 27 日注册。